Even though being approved by the FDA as a highly effective treatment option for patients with relapsed or refractory leukemia with KMT2A‐rearrangements or NPM1‐mutations, roughly 50% of patients show no clinical response.65, 262. This evidence concerns the gene NPM1 and leukemia.